To include your compound in the COVID-19 Resource Center, submit it here.

Irofulven hydroxymethylacylfulvene (MGI 114): Began Phase III testing

Additional interim results from MOGN's ongoing 50-patient Phase II pancreatic cancer trial are

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE